156 related articles for article (PubMed ID: 38401189)
21. Medicinal applications of (benz)imidazole- and indole-based macrocycles.
Patil SA; Patil SA; Patil R
Chem Biol Drug Des; 2017 Apr; 89(4):639-649. PubMed ID: 28371443
[TBL] [Abstract][Full Text] [Related]
22. Conformationally based design of macrocycles as antitumor agents.
Singh EK; Sellers RP; Alexander LD; McAlpine SR
Curr Opin Drug Discov Devel; 2008 Jul; 11(4):544-52. PubMed ID: 18600570
[TBL] [Abstract][Full Text] [Related]
23. Structural and conformational determinants of macrocycle cell permeability.
Over B; Matsson P; Tyrchan C; Artursson P; Doak BC; Foley MA; Hilgendorf C; Johnston SE; Lee MD; Lewis RJ; McCarren P; Muncipinto G; Norinder U; Perry MW; Duvall JR; Kihlberg J
Nat Chem Biol; 2016 Dec; 12(12):1065-1074. PubMed ID: 27748751
[TBL] [Abstract][Full Text] [Related]
24. Structure-Based Design of High-Affinity Macrocyclic FKBP51 Inhibitors.
Bauder M; Meyners C; Purder PL; Merz S; Sugiarto WO; Voll AM; Heymann T; Hausch F
J Med Chem; 2021 Mar; 64(6):3320-3349. PubMed ID: 33666419
[TBL] [Abstract][Full Text] [Related]
25. Modulation of the Passive Permeability of Semipeptidic Macrocycles: N- and C-Methylations Fine-Tune Conformation and Properties.
Comeau C; Ries B; Stadelmann T; Tremblay J; Poulet S; Fröhlich U; Côté J; Boudreault PL; Derbali RM; Sarret P; Grandbois M; Leclair G; Riniker S; Marsault É
J Med Chem; 2021 May; 64(9):5365-5383. PubMed ID: 33750117
[TBL] [Abstract][Full Text] [Related]
26. Property-Driven Development of Passively Permeable Macrocyclic Scaffolds Using Heterocycles.
Saunders GJ; Yudin AK
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202206866. PubMed ID: 35687524
[TBL] [Abstract][Full Text] [Related]
27. Cyclophilin Succumbs to a Macrocyclic Chameleon.
Doak BC; Kihlberg J
J Med Chem; 2018 Nov; 61(21):9469-9472. PubMed ID: 30359012
[TBL] [Abstract][Full Text] [Related]
28. Recent Advances in Macrocyclic Drugs and Microwave-Assisted and/or Solid-Supported Synthesis of Macrocycles.
Sun D
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164274
[TBL] [Abstract][Full Text] [Related]
29. Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.
Corte JR; Fang T; Osuna H; Pinto DJ; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Decicco CP; Wexler RR; Quan ML
J Med Chem; 2017 Feb; 60(3):1060-1075. PubMed ID: 28085275
[TBL] [Abstract][Full Text] [Related]
30. Heck Macrocyclization in Forging Non-Natural Large Rings including Macrocyclic Drugs.
Cai J; Sun B; Yu S; Zhang H; Zhang W
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175956
[TBL] [Abstract][Full Text] [Related]
31. Tackling the conformational sampling of larger flexible compounds and macrocycles in pharmacology and drug discovery.
Chen IJ; Foloppe N
Bioorg Med Chem; 2013 Dec; 21(24):7898-920. PubMed ID: 24184215
[TBL] [Abstract][Full Text] [Related]
32. Artificial Macrocycles by Ugi Reaction and Passerini Ring Closure.
Abdelraheem EM; Kurpiewska K; Kalinowska-Tłuścik J; Dömling A
J Org Chem; 2016 Oct; 81(19):8789-8795. PubMed ID: 27598302
[TBL] [Abstract][Full Text] [Related]
33. Current Trends in Macrocyclic Drug Discovery and beyond-Ro5.
Alihodžić S; Bukvić M; Elenkov IJ; Hutinec A; Koštrun S; Pešić D; Saxty G; Tomašković L; Žiher D
Prog Med Chem; 2018; 57(1):113-233. PubMed ID: 29680148
[TBL] [Abstract][Full Text] [Related]
34. The exploration of macrocycles for drug discovery--an underexploited structural class.
Driggers EM; Hale SP; Lee J; Terrett NK
Nat Rev Drug Discov; 2008 Jul; 7(7):608-24. PubMed ID: 18591981
[TBL] [Abstract][Full Text] [Related]
35. Modelling the binding mode of macrocycles: Docking and conformational sampling.
Martin SJ; Chen IJ; Chan AWE; Foloppe N
Bioorg Med Chem; 2020 Jan; 28(1):115143. PubMed ID: 31771798
[TBL] [Abstract][Full Text] [Related]
36. Boronic ester-linked macrocyclic lipopeptides as serine protease inhibitors targeting Escherichia coli type I signal peptidase.
Szałaj N; Lu L; Benediktsdottir A; Zamaratski E; Cao S; Olanders G; Hedgecock C; Karlén A; Erdélyi M; Hughes D; Mowbray SL; Brandt P
Eur J Med Chem; 2018 Sep; 157():1346-1360. PubMed ID: 30196059
[TBL] [Abstract][Full Text] [Related]
37. Diversity-oriented synthesis and cytotoxic activity evaluation of biaryl-containing macrocycles.
Pérez-Labrada K; Cruz-Mendoza MA; Chávez-Riveros A; Hernández-Vázquez E; Torroba T; Miranda LD
Org Biomol Chem; 2017 Mar; 15(11):2450-2458. PubMed ID: 28255584
[TBL] [Abstract][Full Text] [Related]
38. Exploring the synthetic approaches and clinical prowess of established macrocyclic pharmaceuticals.
Sun JG; Nie P; Herdewijn P; Li XJ
Eur J Med Chem; 2024 Jan; 264():116051. PubMed ID: 38104377
[TBL] [Abstract][Full Text] [Related]
39. Macrocyclic inhibitors of Factor XIa: Discovery of alkyl-substituted macrocyclic amide linkers with improved potency.
Corte JR; Yang W; Fang T; Wang Y; Osuna H; Lai A; Ewing WR; Rossi KA; Myers JE; Sheriff S; Lou Z; Zheng JJ; Harper TW; Bozarth JM; Wu Y; Luettgen JM; Seiffert DA; Quan ML; Wexler RR; Lam PYS
Bioorg Med Chem Lett; 2017 Aug; 27(16):3833-3839. PubMed ID: 28687203
[TBL] [Abstract][Full Text] [Related]
40. Predicting the bioactive conformations of macrocycles: a molecular dynamics-based docking procedure with DynaDock.
Ugur I; Schroft M; Marion A; Glaser M; Antes I
J Mol Model; 2019 Jun; 25(7):197. PubMed ID: 31222506
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
